Navigation Links
Heritage Pharma Announces The Return Of Tetracycline HCI Capsules
Date:10/21/2013

EATONTOWN, N.J., Oct. 21, 2013 /PRNewswire/ -- Heritage Pharmaceuticals Inc. ("Heritage") announced the immediate availability of Tetracycline HCl Capsules, USP in 250 and 500 mg strengths.  This product is the AB rated generic equivalent to the antibiotic Achromycin V and adds to Heritage's robust portfolio of generic oral solid products.  Tetracycline capsules have been on the FDA drug shortage list for the past two years and Heritage is the first generic pharmaceutical manufacturer to reintroduce the product.

About Tetracycline HCl
Tetracycline HCl is indicated for the treatment of various bacterial infections.  The package insert, which is available at www.heritagepharma.com, contains detailed information about the indications, complete side effect profile and prescribing information.

About Heritage
Heritage Pharmaceuticals Inc. is a specialty pharmaceutical company engaged in the development, manufacturing, sales and marketing of generic and legacy branded pharmaceutical products for the U.S. prescription drug market.  Since inception, our customers have experienced the benefits of our continuous product expansion and global alliance network that has produced an impressive portfolio of over 150 products spanning multiple dosage forms. Heritage's products cover a number of therapeutic categories, including but not limited to: oncology, cardiovascular, metabolic disease, anti-infective and pain management.  Whether its oral solids or complex injectables, the Heritage portfolio is poised to continue to rapidly expand and deliver the Value Driven Medicine required to keep our customers competitive in the marketplace.   Let our formula of high quality and consistent supply work for you as we continue to provide affordable healthcare solutions to the U.S. consumer.


'/>"/>
SOURCE Heritage Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. George Rosenkranz to Receive 2013 Biotechnology Heritage Award
2. Heritage-DREAM, National Cancer Institute Breast Cancer Network Inference Prize Announced
3. Heritage Provider Network, UCLA and Open mHealth announce the launch of $100,000 mobile apps health prize challenge
4. MEI Pharmas Mitochondrial Inhibitor ME-344 Shows Preliminary Evidence of Single-Agent Activity in First-in-Human Clinical Study
5. DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Potential Treatment for Three Chemotherapy Resistant Cancers
6. Inovio Pharmaceuticals Therapeutic Vaccine for Hepatitis C Enters Phase I Clinical Trial
7. The Growing Role of Medical Science Liaisons in the Pharmaceutical Industry
8. Sarissa Capital Issues Open Letter Regarding Astex Pharmaceuticals
9. Adamas Pharmaceuticals Presents Positive Clinical Data For ADS-5102, A Treatment For Levodopa-Induced Dyskinesia, At The World Parkinsons Congress
10. Adamas Pharmaceuticals presenta datos clínicos positivos para ADS-5102, un tratamiento para la disquinesia inducida por levodopa, en el Congreso Mundial del Parkinson
11. Valeant Pharmaceuticals Announces Partnership With National Coalition Against Domestic Violence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... LONDON , May 30, 2016 ... to eliminate viral hepatitis by 2030. At the 69 th ... first ever Global Viral Hepatitis Strategy, signalling the greatest global ... sets a goal of eliminating hepatitis B and C by ... which, if reached, will reduce annual deaths by 65% and ...
(Date:5/30/2016)... DUBAI , May 30, 2016 ... parents of premature babies to seek an eye examination ... avoid blinding condition     Moorfields Eye ... Hospital in London , has identified premature babies ... vision problems, because of their particular vulnerability to retinopathy of prematurity ...
(Date:5/27/2016)... 2016 According to the 2016 ... driving ambulatory blood pressure monitoring system market growth. With ... ability to respond to different pressure rates, leading to ... to various cardiovascular disorders such as heart failure, stroke, ... are growing in prevalence each year. WHO estimates that ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... , ... Splashtop Inc., the worldwide leader in high performance cross-screen access, ... leading provider of secure mobile remote access solution for Japan enterprises. , ... solution. Splashtop for CACHATTO will be available as an integrated add-on secure ...
(Date:5/31/2016)... ... , ... DDL, Inc. announced today it has expanded the scope of its ... 594-1 and ISO 594-2 testing for conical (Luer) fittings. , A conical Luer ... devices (e.g. a syringe and hypodermic needle) that carry small volumes of fluids. There ...
(Date:5/31/2016)... ... 2016 , ... Like jewels in a crown, the multiple awards presented to ... to Ontario’s leading day spa and one of Canada’s few accredited 5 Star Spas! ... concept to combine spa services with hair and beauty services and has ...
(Date:5/31/2016)... ... May 31, 2016 , ... The Orthopaedic Research and Education ... , David G. Lewallen, MD, began his term as president in March, succeeding ... Parks, MD, is OREF’s new president-elect. Richard F. Kyle, MD, will serve as chair, ...
(Date:5/31/2016)... Aviv (PRWEB) , ... May 31, 2016 , ... ... the May 4, 2016 Cool Vendors in Security Infrastructure Protection report by Gartner1 ... and publishes a series of research reports evaluating these innovative vendors and their ...
Breaking Medicine News(10 mins):